Literature DB >> 23223915

Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.

Abdelhay A Ebade1, Mohamed A Khalil, Ahmed K Mohamed.   

Abstract

PURPOSE: To compare the effectiveness of levosimendan and dobutamine in reducing pulmonary artery pressure (PAP) and increasing cardiac output for children undergoing cardiac surgery. PATIENTS AND METHODS: The study included 50 patients with high systolic pulmonary artery pressure (PAP) undergoing surgical repair of cardiac septal defects. Patients were randomly allocated to two equal groups: group L received levosimendan and group D received dobutamine. PAP was measured preoperatively, by use of transthoracic echocardiography (baseline), intraoperatively, directly, by use of a 22-gauge catheter inserted in the pulmonary artery, and postoperatively, by use of transesophageal echocardiography (TEE). Cardiac index (CI) was recorded by use of a transesophageal 4-MHz Doppler probe.
RESULTS: Both drugs significantly reduced PAP compared with the level at the time of induction of anesthesia. Mean PAP measurement before chest closure, 1 and 20 h after ICU admission were significantly lower for patients who received levosimendan (32.7 ± 4.1, 25.8 ± 2.8, 19.8 ± 2 mmHg, respectively) than for those who received dobutamine (37.6 ± 2.75, 32.8 ± 2.36, 26.5 ± 2.2 mmHg, respectively). Both drugs significantly improved CI compared with its level at the time of induction of anesthesia. Mean CI measurements 5 min after weaning from cardiopulmonary bypass (CPB) until 20 h after ICU admission were significantly higher for patients who received levosimendan than for those who received dobutamine (3.55 ± 0.35, 3.8 ± 0.36, 3.81 ± 0.34, respectively, in group L vs. 3.4 ± 0.36, 3.6 ± 0.33, 3.66 ± 0.29, respectively, in group D).
CONCLUSION: Levosimendan is better than dobutamine for treatment of pulmonary hypertension of children undergoing cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223915     DOI: 10.1007/s00540-012-1537-9

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  28 in total

1.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

Authors:  M S Nieminen; J Akkila; G Hasenfuss; F X Kleber; L A Lehtonen; V Mitrovic; O Nyquist; W J Remme
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

Authors:  J Lilleberg; M S Nieminen; J Akkila; L Heikkilä; A Kuitunen; L Lehtonen; K Verkkala; S Mattila; M Salmenperä
Journal:  Eur Heart J       Date:  1998-04       Impact factor: 29.983

3.  Myocardial efficiency during levosimendan infusion in congestive heart failure.

Authors:  H Ukkonen; M Saraste; J Akkila; J Knuuti; M Karanko; H Iida; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

4.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy.

Authors:  M Rabinovitch; T Bothwell; B N Hayakawa; W G Williams; G A Trusler; R D Rowe; P M Olley; E Cutz
Journal:  Lab Invest       Date:  1986-12       Impact factor: 5.662

5.  Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial.

Authors:  Pasi Lahtinen; Otto Pitkänen; Pekka Pölönen; Anu Turpeinen; Vesa Kiviniemi; Ari Uusaro
Journal:  Crit Care Med       Date:  2011-10       Impact factor: 7.598

6.  Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.

Authors:  H Ukkonen; M Saraste; J Akkila; M J Knuuti; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki
Journal:  Clin Pharmacol Ther       Date:  1997-05       Impact factor: 6.875

7.  [Intensive care for newborns and babies of the first year of life with acute heart failure after cardiosurgical interventions].

Authors:  G V Lobacheva; A V Khar'kin; A F Manerova; E R Dzhobava
Journal:  Anesteziol Reanimatol       Date:  2010 Sep-Oct

8.  Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.

Authors:  Mona Momeni; Jean Rubay; Amine Matta; Marie-Thérèse Rennotte; Francis Veyckemans; Alain Jean Poncelet; Stéphan Clement de Clety; Christine Anslot; Ryad Joomye; Thierry Detaille
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-09-09       Impact factor: 2.628

9.  Are transoesophageal Doppler parameters a reliable guide to paediatric haemodynamic status and fluid management?

Authors:  S M Tibby; M Hatherill; A Durward; I A Murdoch
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

10.  Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

Authors:  G Hasenfuss; B Pieske; M Castell; B Kretschmann; L S Maier; H Just
Journal:  Circulation       Date:  1998-11-17       Impact factor: 29.690

View more
  10 in total

Review 1.  Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.

Authors:  Johanna Hummel; Gerta Rücker; Brigitte Stiller
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

Review 2.  The Perspective of the Intensivist on Inotropes and Postoperative Care Following Pediatric Heart Surgery: An International Survey and Systematic Review of the Literature.

Authors:  Peter P Roeleveld; J C A de Klerk
Journal:  World J Pediatr Congenit Heart Surg       Date:  2017-11-01

Review 3.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 4.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08

5.  Levosimendan for Pediatric Anomalous Left Coronary Artery From the Pulmonary Artery Undergoing Repair: A Single-Center Experience.

Authors:  Chunrong Wang; Junsong Gong; Sheng Shi; Jianhui Wang; Yuchen Gao; Sudena Wang; Yong G Peng; Jing Song; Yuefu Wang
Journal:  Front Pediatr       Date:  2018-08-14       Impact factor: 3.418

Review 6.  Levosimendan for Perioperative Cardioprotection: Myth or Reality?

Authors:  Elpidio Santillo; Monica Migale; Carlo Massini; Raffaele Antonelli Incalzi
Journal:  Curr Cardiol Rev       Date:  2018

7.  Levosimendan in pulmonary hypertension and right heart failure.

Authors:  Mona Sahlholdt Hansen; Asger Andersen; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2018-07-06       Impact factor: 3.017

8.  Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

Authors:  Annette Dorothea Rieg; Said Suleiman; Nina Andrea Bünting; Eva Verjans; Jan Spillner; Heike Schnöring; Sebastian Kalverkamp; Thomas Schröder; Saskia von Stillfried; Till Braunschweig; Gereon Schälte; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 9.  Levosimendan: current data, clinical use and future development.

Authors:  M S Nieminen; S Fruhwald; L M A Heunks; P K Suominen; A C Gordon; M Kivikko; P Pollesello
Journal:  Heart Lung Vessel       Date:  2013

10.  Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.

Authors:  Fabio Guarracino; Matthias Heringlake; Bernard Cholley; Dominique Bettex; Stefaan Bouchez; Vladimir V Lomivorotov; Angela Rajek; Matti Kivikko; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2018-01       Impact factor: 3.105

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.